XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

						For the Three Months Ended March 31, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	54,149					$	—					$	8,501					$	62,650
Residents fees and services						—						308,126						—						308,126
Total revenues						54,149						308,126						8,501						370,776
Expenses:
Property operating expenses						23,897						283,416						291						307,604
Depreciation and amortization						20,740						46,922						2,471						70,133
General and administrative						—						—						7,568						7,568
Acquisition and certain other transaction related costs						—						—						86						86
Impairment of assets						12,142						—						—						12,142
Total expenses						56,779						330,338						10,416						397,533
Loss on sale of properties						(5,874)						—						—						(5,874)
Gains on equity securities, net						—						—						—						—
Interest and other income						—						—						2,237						2,237
Interest expense						(222)						(68)						(57,286)						(57,576)
Loss before income tax expense and equity in net earnings of investees						(8,726)						(22,280)						(56,964)						(87,970)
Income tax expense						—						—						(187)						(187)
Equity in net earnings of investees						1,613						—						285						1,898
Net loss						$	(7,113)					$	(22,280)					$	(56,866)					$	(86,259)

						As of March 31, 2024
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets						$	1,834,609					$	3,103,540					$	409,888					$	5,348,037

						For the Three Months Ended March 31, 2023
						Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Revenues:
Rental income						$	57,022					$	—					$	9,416					$	66,438
Residents fees and services						—						279,592						—						279,592
Total revenues						57,022						279,592						9,416						346,030
Expenses:
Property operating expenses						23,515						262,329						236						286,080
Depreciation and amortization						20,035						42,152						2,613						64,800
General and administrative						—						—						5,873						5,873
Acquisition and certain other transaction related costs						—						—						93						93
Impairment of assets						2,308						3,617						—						5,925
Total expenses						45,858						308,098						8,815						362,771
Gain on sale of properties						—						1,233						—						1,233
Gains on equity securities, net						—						—						8,126						8,126
Interest and other income						—						—						4,195						4,195
Interest expense						(109)						(271)						(47,400)						(47,780)
Loss on modification or early extinguishment of debt						—						—						(1,075)						(1,075)
Income (loss) before income tax benefit and equity in net losses of investees						11,055						(27,544)						(35,553)						(52,042)
Income tax benefit						—						—						31						31
Equity in net losses of investees						(647)						—						—						(647)
Net income (loss)						$	10,408					$	(27,544)					$	(35,522)					$	(52,658)

			As of December 31, 2023
			Medical Office and Life Science Portfolio						SHOP						Non-Segment						Consolidated
Total assets			$	1,866,422					$	3,134,978					$	444,736					$	5,446,136

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration